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RESEARCH ARTICLE
Genetic Modifiers of Ambulation in the
Cooperative International Neuromuscular
Research Group Duchenne Natural
History Study
Luca Bello, MD,1,2 Akanchha Kesari, PhD,1 Heather Gordish-Dressman, PhD,1
Avital Cnaan, PhD,1,3 Lauren P. Morgenroth, MS, CGC,1 Jaya Punetha, PhDc,1,4
Tina Duong, MPT,1 Erik K. Henricson, MPH,5 Elena Pegoraro, MD, PhD,2
Craig M. McDonald, MD,5 and Eric P. Hoffman, PhD,1,4
on behalf of the Cooperative International Neuromuscular Research Group
Investigators
Objective: We studied the effects of LTBP4 and SPP1 polymorphisms on age at loss of ambulation (LoA) in a multi-
ethnic Duchenne muscular dystrophy (DMD) cohort.
Methods: We genotyped SPP1 rs28357094 and LTBP4 haplotype in 283 of 340 participants in the Cooperative Inter-
national Neuromuscular Research Group Duchenne Natural History Study (CINRG-DNHS). Median ages at LoA were
compared by Kaplan–Meier analysis and log-rank test. We controlled polymorphism analyses for concurrent effects
of glucocorticoid corticosteroid (GC) treatment (time-varying Cox regression) and for population stratification (multi-
dimensional scaling of genome-wide markers).
Results: Hispanic and South Asian participants (n5 18, 41) lost ambulation 2.7 and 2 years earlier than Caucasian
subjects (p50.003, <0.001). The TG/GG genotype at SPP1 rs28357094 was associated to 1.2-year-earlier median
LoA (p50.048). This difference was greater (1.9 years, p50.038) in GC-treated participants, whereas no difference
was observed in untreated subjects. Cox regression confirmed a significant effect of SPP1 genotype in GC-treated
participants (hazard ratio5 1.61, p50.016). LTBP4 genotype showed a direction of association with age at LoA as
previously reported, but it was not statistically significant. After controlling for population stratification, we confirmed
a strong effect of LTBP4 genotype in Caucasians (2.4 years, p5 0.024). Median age at LoA with the protective
LTBP4 genotype in this cohort was 15.0 years, 16.0 for those who were treated with GC.
Interpretation: SPP1 rs28357094 acts as a pharmacodynamic biomarker of GC response, and LTBP4 haplotype modi-
fies age at LoA in the CINRG-DNHS cohort. Adjustment for GC treatment and population stratification appears cru-
cial in assessing genetic modifiers in DMD.
ANN NEUROL 2015;77:684–696
Duchenne muscular dystrophy (DMD) is caused bythe absence of the protein dystrophin in myofibers,
due to truncating dystrophin gene mutations.1 Despite
this homogeneous molecular defect, variability in pheno-
type severity is commonly observed, for example, variable
age at loss of ambulation (LoA). This is due to
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environmental factors, such as implementation of stand-
ards of care (glucocorticoid corticosteroid [GC] treat-
ment, physical therapy, management of contractures,
fracture prevention),2,3 and to the genetic background.
Two genetic modifiers of DMD, that is, common poly-
morphisms that modulate disease severity combined with
a pathogenic mutation, have been described: a single
nucleotide polymorphism (SNP) in the promoter of the
SPP1 (secreted phosphoprotein 1, or osteopontin) gene,
and a coding LTBP4 (latent transforming growth factor
b binding protein 4) haplotype. The association of the
SPP1 rs28357094 rare G allele with earlier LoA, in a
dominant inheritance model, was originally reported in
106 Italian DMD patients.4 SPP1 encodes an inflamma-
tory cytokine involved in tissue damage response, and is
part of the transforming growth factor b (TGFb) path-
way.5 The rs28357094 polymorphism alters transcription
at baseline6 and in response to steroid hormones.7
The LTBP4 locus was identified by genome-wide
mapping in a murine model of muscular dystrophy.8
Subsequently, a LTBP4 haplotype was associated with
variable LoA in 254 patients with severe dystrophinop-
athy (United Dystrophinopathy Project).9 The haplotype
consists of 4 coding SNPs in strong linkage disequili-
brium (LD), 1 of which, rs10880, was independently
associated with age at LoA. Homozygotes for the minor
allele T at rs10880 (T1140M), in LD with the haplotype
IAAM, showed later LoA. The proposed mechanism is
that the IAAM protein isoform results in a more stable
latent TGFb complex, reducing TGFb signaling. In the
same paper, the authors found no association of SPP1
genotype with age at LoA.
Validation of genetic associations in independent
cohorts is essential to establish genetic modifiers of Men-
delian diseases,10 but may be exaggerated or obscured by
confounding variables, such as ancestry-dependent differ-
ences in allele frequency and haplotype configuration,
which associate with variations of standards of care and
other environmental factors, and lead to population strat-
ification.11–13 Disparities in diagnostics,14 standards of
care,15 and phenotype severity16,17 between DMD
patients of different ethnic backgrounds have been
reported. The Cooperative International Neuromuscular
Research Group Duchenne Natural History Study
(CINRG-DNHS)18 comprises participants from 20 cen-
ters on 4 continents, constituting an ethnically diverse
cohort.
We have expanded analysis of the CINRG-DNHS
cohort, from the baseline cross-sectional analysis of grip
strength in 156 participants4 to a longitudinal study
(average follow-up 4 years) of all 340 participants.18,19
Here we sought to test the effect of SPP1 and LTBP4
genotypes on LoA in the CINRG-DNHS population,
controlling for GC treatment and population stratifica-
tion. After controlling for these confounding factors, we
find an association of both loci with LoA.
Subjects and Methods
The institutional review board or ethics review board at each
participating institution approved the study protocol, and con-
sent and assent documents. Informed consent/assent was
obtained for each participant prior to conducting study
procedures.
Inclusion and Exclusion Criteria
The inclusion and exclusion criteria for the CINRG-DNHS
have been previously described.18,19 Recruitment was aimed at
obtaining a population representing an age span from very
young to adult (age 2–28 years at baseline). Conversely, recruit-
ment was not specifically aimed at obtaining subpopulations
with homogeneous ancestry for genetic association analysis. For
all analyses focused on SPP1 and LTBP4 genotypes, we
excluded patients with no available genomic DNA for SNP
genotyping.
LoA and GC Treatment Definitions
LoA was defined as patient-reported continuous wheelchair use,
verified by inability to walk 10m unassisted. GC treatment his-
tory was recorded both retrospectively at baseline, and longitu-
dinally during the study, and the population was dichotomized
into treated at least 1 year with GCs before LoA, and untreated
or treated <1 year before LoA. This included patients who had
gone on and off GC treatment 1 or more times, but were
cumulatively treated for at least 1 year before LoA. The 1-year
treatment threshold was chosen based on the clinical rationale
that a long-term effect of GC treatment, such as delaying dis-
ease milestones, cannot be reasonably expected from short-term
treatment. Data were also reanalyzed with a 6-month treatment
threshold, as in Flanigan et al,9 to compare LTBP4 data with
the same methodology as the original report of this modifier.
Race and Ethnicity Definitions
Self-identification of participants into 1 of the following racial
categories was recorded: African American, Asian, Caucasian,
Mixed, or Other; self-identification into non-Hispanic or His-
panic ethnicity was specified as a separate option, according to
official US Census categories (http://www.whitehouse.gov/omb/
fedreg_1997standards/). Here, we clustered this information
into the following groups: African American, Asian, non-
Hispanic Caucasian, Hispanic Caucasian, Hispanic (ie, partici-
pants self-identifying their ethnicity as Hispanic, and race as
Mixed/Other), and Other (ie, participants self-identifying their
ethnicity as non-Hispanic, and race as Mixed or Other); and
distinguished as South Asian participants recruited at the
Study Center in Chennai, India (for these participants, no
DNA samples were available because of local regulations that
did not allow the shipment of DNA for the purposes of our
study).
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Targeted Genotyping
Targeted genotyping was carried out by TaqMan allele discrimi-
nation assays. For SPP1 rs28357094, a dominant model for the
minor allele G was adopted.4 For LTBP4 association studies,
we focused mainly on the rs10880 SNP (T1140M), which is in
strong LD with the IAAM haplotype, and showed an independ-
ent association with LoA in the original report, in a recessive
model.9 Focusing initially on a single significant SNP allowed
inclusion of larger numbers of participants in the analyses. To
confirm association with the full haplotype in carriers of the
rs10880 T allele, we genotyped rs2303729 (V194I), rs1131620
(T787A), and rs1051303 (T820A). LTBP4 haplotypes were
phased with PLINK,20 and median ages at LoA were calculated
for all observed haplotype configurations, in all those patients
for whom haplotypes could be phased with at least 90%
probability.
Multidimensional Scaling Analysis
Genotype data from the Illumina (San Diego, CA) HumanE-
xome Chip was available for 175 participants. These were not
selected by ethnicity, nor any phenotype-related data points,
but solely on the base of available DNA quantity and quality.
Although mainly focusing on coding regions, the chip contains
ancestry markers and other common variant markers (30,000)
that ensure sufficient genome-wide coverage for multidimen-
sional scaling (MDS) analysis. Chip design information is
publicly available at http://genome.sph.umich.edu/wiki/Exo-
me_Chip_Design#Illumina_Exome_Arrays. Genotypes were
called from raw intensity data with Genome Studio software,
and data was exported into PLINK format with the dedicated
plug-in software by Illumina. PLINK was used for data cleaning
and MDS analysis.20 Subjects with >10% missed calls and
SNPs with >5% missed calls were removed to ensure data
quality.21 MDS analysis was based on the calculation of
genome-wide identity-by-state pairwise distances, on a set of
“pruned” genome-wide markers in no significant LD with each
other, using the PLINK whole genome association analysis tool-
set.20 LD-based pruning parameters were the following: 50-
SNP window size, 5-SNP window slide at each step, variance
inflation factor threshold5 2. The 2 highest ranking principal
components were plotted.
Grouping Criteria for Analyses of Race/Ethnicity
Differences in GC Treatment and LoA
Median LoA and GC treatment rates were calculated in partici-
pants with different self-identified race/ethnicities in the whole
DNHS cohort of 340 patients, grouped as defined above.
Grouping Criteria for Analyses of SNP Effect on
LoA
SNP effects on LoA were analyzed in the whole cohort with
available genomic DNA for genotyping, and in a subcohort of
participants of Caucasian ancestry, identified by MDS analysis.
In both cohorts, analyses were carried out in 3 groupings based
on GC treatment: all participants regardless of treatment; GC-
treated participants (at least 1 year while ambulatory as defined
above); GC-untreated participants (including those treated <1
year while ambulatory, as defined above). Data were also reana-
lyzed with a 6-month GC treatment threshold, as explained
above.
A flow diagram of participant grouping, with correspond-
ing planned analyses, participant numbers, and GC treatment
rates, is shown in Figure 1.
Statistical Methods
Rates of GC treatment between self-identified racial and ethnic
subgroups were compared by chi-square test. Loss of ambula-
tion was studied in a time to event model with age as the time
variable, and LoA as the failure event. Ambulatory participants
were censored at the age of last follow-up. Median ages at LoA
in race/ethnicity and genotype subgroups were based on the
empiric survival curve from a Kaplan–Meier (KM) curve calcu-
lation, and compared by log-rank test. For SPP1 and LTBP4
genotypes, patients were grouped based on inheritance models
specified above. Additionally, concurrent effects of GC treat-
ment and SNP genotype were analyzed in a Cox regression
model, with a time-varying GC treatment covariate (on/off
treatment defined for all participants at the time of each event).
Statistical significance was set at p< 0.05. Genomics Suite 6.6
(Partek, St Louis, MO) and Stata v13 (StataCorp, College Sta-
tion, TX) were used for statistical analyses.
Results
Distribution by Race/Ethnicity and GC
Treatment
Self-identified race/ethnicity in the 340 participants
enrolled in the CINRG-DNHS was distributed as fol-
lows: 225 (66%) Caucasian, 23 (7%) Hispanic-
Caucasian, 41 (12%) South Asian, 18 (5%) Hispanic, 14
(4%) Asian, 6 (2%) African American, and 13 (4%)
Other. Of note, the South Asian group was the only one
entirely referring to a single study center (Chennai,
India).
GC treatment was administered for at least 1 year
before LoA to 252 of 340 participants (74%). There
were differences in the proportion of participants treated
for at least 1 year with GCs between self-identified
racial–ethnic subgroups. Overall, participants self-
identifying as Caucasian (both Hispanic and non-
Hispanic ethnicity) were more often treated for at least 1
year than other participants: 191 of 248 (77%) versus 61
of 92 (65%), chi-square p5 0.045 (Table 1). This com-
parison might be biased by different proportions of
younger, ambulatory GC-naive participants, as opposed
to nonambulatory participants who did not receive treat-
ment before LoA. When analyzing nonambulatory partic-
ipants only, we found a trend in the same direction;
nonambulatory Caucasians treated at least 1 year while
ambulatory were 113 of 162 (70%) versus other ethnic-
ities 39 of 67 (58%, chi-square p5 0.09, see Table 1).
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Age at LoA and GC Treatment Show
Differences between Self-Reported Ethnic
Subgroups
Median age at LoA was 12.4 years in the non-Hispanic
Caucasian population (n5 225). Compared to this
numerically predominant group, median age at LoA was
significantly earlier in the Hispanic (n5 18, 9.7 years,
log-rank p5 0.003) and South Asian (n5 41, 10.4 years,
p< 0.001) subpopulations. Median LoA was earlier in
the Asian subpopulation (n5 14, 11.3 years), and later
TABLE 1. Number and Percentage of Participants Treated with Glucocorticoid Corticosteroids at Least 1 Year
While Ambulatory, Grouped by Self-Identified Race and Ethnicity
Self-Identified Race and Ethnicity All Participants Nonambulatory Ambulatory
African American 2/6 (33%) 0/4 (0%) 2/2 (100%)
Asian 9/14 (64%) 8/13 (62%) 1/1 (100%)
Caucasian
Non-Hispanic 173/225 (77%) 102/146 (70%) 71/79 (90%)
Hispanic 18/23 (78%) 11/16 (69%) 7/7 (100%)
Hispanic 8/18 (44%) 6/16 (37%) 2/2 (100%)
Other 12/13 (92%) 5/6 (83%) 7/7 (100%)
South Asian 30/41 (73%) 20/28 (71%) 10/13 (77%)
Overall 251/340 (74%) 151/229 (66%) 100/111 (90%)
FIGURE 1: Flow diagram of analysis plan and population grouping. Subgroups included in different analyses are shown, start-
ing from the top with the whole Duchenne Natural History Study (DNHS) cohort, and in subsequent steps excluding patients
with no available DNA for genotyping; subjects with no available genome-wide markers for multidimensional scaling analysis
for population stratification; and subjects leading to population stratification. Thick-border boxes indicate groups selected for
specific analyses. CINRG5Cooperative International Neuromuscular Research Group; GC5glucocorticoid corticosteroid;
LoA5 loss of ambulation; MDS5multidimensional scaling; SNP5 single nucleotide polymorphism.
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in Hispanic-Caucasian (n5 23, 13.0 years) and African
American subpopulations (n5 6, 14.2), but differences
with non-Hispanic Caucasians were not statistically
significant.
Genotyping Results
Genomic DNA samples for targeted genotyping were
available for 283 of 340 participants. The 57 patients
excluded because of unavailability of DNA samples com-
prised all 41 patients followed at the study center in
Chennai, India, as regulatory authorities did not allow
participation in this part of the study.
Minor allele frequencies (MAFs) for SPP1
rs28357094 and LTBP4 rs10880 in the CINRG-DNHS
population, broken down by ethnic subgroups, are shown
in Table 2, compared to MAFs in continental reference
populations from the 1000 Genomes project (http://
www.1000genomes.org/). For both SNPs, the MAF in
the numerically preponderant Caucasian population was
slightly lower than in the 1000 Genomes reference EUR
population (0.18 vs 0.24 for SPP1 rs2835704, and 0.36
vs 0.41 for LTBP4 rs10880).
For SPP1 rs28357094, MAFs in Asian and His-
panic populations were higher than reference. These
findings might be suggestive of population admixture.
Both SNPs were in Hardy–Weinberg equilibrium
(HWE).
LTBP4 haplotypes could be phased with 90% prob-
ability in 242 participants, including 28 of 32 TT homo-
zygotes for LTBP4 rs10880. Of these, 24 of 28 were
homozygotes for the full IAAM haplotype based on
rs2303729, rs1131620, and 1051303 genotypes, whereas
4 of 28 participants were heterozygotes for other rare
haplotypes (VAAM or VTTM). Haplotype distributions
in different ethnic subgroups, along with median age at
LoA calculated for all observed haplotype configurations
(with standard errors [SEs] and 95% confidence inter-
vals), are shown in detail in Supplementary Table 1. All
SNPs in the LTBP4 haplotype were in HWE.
Association Analyses in the Whole Genotyped
Cohort: Effect of SPP1 on LoA Is GC
Treatment–Dependent in the DNHS Population
Analyses relative to SPP1 and LTBP4 genotypes were
limited to 283 patients with available genomic DNA
samples (see Fig 1). Of these, 279 (because of limited
availability of genomic DNA for a few participants) were
successfully genotyped for SPP1 rs28357094. Median
ages at LoA for genotype groups and results of log-rank
and Cox regression analyses are summarized in Table 3.
Median ages at LoA were 11.8 years in 84 participants
carrying the minor allele (TG/GG), and 13.0 years in
195 participants carrying the TT genotype (log-rank
p5 0.048, Fig 2A). This closely reproduces the method-
ology of the previously reported association of
rs28357094 genotype with LoA in 106 Italian patients,4
representing an independent validation of association
with this phenotype. In the Cox regression model with
GC treatment as time-varying covariate, the hazard ratio
(HR)6 SE for TG/GG genotype was 1.226 0.20
(p5 nonsignificant [n.s.]). The HR for GC treatment
was 0.416 0.07 (p< 0.001).
In 274 participants genotyped for LTBP4 rs10880,
median ages at LoA were 12.0 years in 242 participants
with the CC/CT genotype, and 13.9 years in 32 homo-
zygotes for the minor allele T (log-rank p5 0.20, Fig
3A). In the Cox regression model with GC treatment as
time-varying covariate, HR for the TT genotype was
TABLE 2. MAFs for SPP1 rs28357094 and LTBP4 rs10880 Compared to 1000G MAFs
Population SPP1 rs28357094 LTBP4 rs10880
DNHS 1000G DNHS 1000G
African American, n5 6 0.10 0.04 (AFR) 0.30 0.51 (AFR)
Asian, n5 14 0.08 0.00 (ASN) 0.31 0.29 (ASN)
non-Hispanic Caucasian, n5 225 0.18 0.24 (EUR) 0.36 0.41 (EUR)
Hispanic Caucasian, n5 23 0.11 0.24 (EUR) 0.34 0.41 (EUR)
Hispanic, n5 18 0.18 0.14 (AMR) 0.31 0.27 (AMR)
Other, n5 13 0.13 0.12 0.31 0.38
Overall 0.17 0.12 0.35 0.38
MAFs for 1000G refer to a continental reference population (in parentheses), or to the whole project if not otherwise specified.
1000G5 1000 Genomes project; DNHS5Duchenne Natural History Study; MAF5minor allele frequency.
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0.786 0.18 (p5 n.s.). The HR for GC treatment was
0.396 0.06 (p< 0.001). In this and the following analy-
ses, participant numbers for the 2 genotyped SNPs differ
slightly, because of limited availability of genomic DNA
for a few participants.
These data show directions of association as previ-
ously reported (SPP1 TG/GG genotype: earlier age at
LoA; LTBP4 TT genotype: later age at LoA). SPP1 was
statistically significant in the log-rank comparison of
median LoA, but not in the GC treatment–adjusted Cox
model, whereas LTBP4 did not reach statistical signifi-
cance. Findings for LTBP4 were similar for 24 of 32
rs10880 TT homozygotes carrying the whole IAAM/
IAAM haplotype (data not shown).
When grouping only GC-treated participants (at least
1 year of treatment while ambulatory), we observed a 1.9-
year difference in median LoA between SPP1 rs28357094
genotypes; median ages at LoA were 12.0 and 13.9 years for
FIGURE 2: Kaplan–Meier plots of age at loss of ambulation grouped by SPP1 rs28357094 genotype. (A) All patients genotyped
for SPP1 rs28357094, including all races and ethnicities (n5279), grouped 2 ways by rs28357094 genotype (black line5TT;
gray line5TG/GG). (B) All patients genotyped for SPP1 rs28357094, including all races and ethnicities (n5279), grouped 4
ways by rs28357094 genotype (black lines5TT; gray lines5TG/GG) and GC treatment (continuous lines5 at least 1 year while
ambulatory; dashed lines5<1 year or untreated). (C) Caucasian cohort controlled for population stratification and genotyped
for SPP1 rs28357094 (n5116), grouped 2 ways by rs28357094 genotype (black line5TT; gray line5TG/GG). (D) Caucasian
cohort controlled for population stratification and genotyped for SPP1 rs28357094 (n5116), grouped 4 ways by rs28357094
genotype (black lines5TT; gray lines5TG/GG) and GC treatment (continuous lines5 at least 1 year while ambulatory; dashed
lines5<1 year or untreated).
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n5 63 GG/GT and n5 150 TT, respectively (log-rank
p5 0.032, see Fig 2B). In the Cox regression model with
GC treatment as time-varying covariate, the HR for TG/
GG genotype was 1.616 0.32 (p5 0.016). The HR for
GC treatment was 1.306 0.49 (p5 n.s.). Median ages at
LoA were identical (10.0 years) for untreated participants
with different SPP1 genotypes (n5 21 and 45, respectively,
see Fig 2B). This suggests that the SPP1 locus may be a
pharmacodynamic marker for GC response, rather than
directly modifying DMD severity.
As for the LTBP4 rs10880 genotype, median ages
at LoA in GC-treated participants were 13.3 and 13.9
years for the CC/CT and TT genotype, n5 178 and 27,
respectively (log-rank p5 n.s., see Fig 3B). In the Cox
regression model with GC treatment as time-varying
covariate, the HR for the TT genotype was 0.746 0.20
(p5 n.s.). The HR for GC treatment was 1.086 0.40
(p5 n.s.). The number of untreated participants with the
rare recessive genotype was too small for a meaningful
comparison (n5 64 and 5, see Fig 3B).
FIGURE 3: Kaplan–Meier plots of age at loss of ambulation grouped by LTBP4 rs10880 genotype. (A) All patients genotyped
for LTBP4 rs10880, including all races and ethnicities (n5274), grouped 2 ways by rs10880 genotype (black line5TT; gray
line5CC/CT). (B) All patients genotyped for LTBP4 rs10880, including all races and ethnicities (n5274), grouped 4 ways by
rs10880 genotype (black line5TT; gray line5CC/CT) and GC treatment (continuous lines5at least 1 year while ambulatory;
dashed lines5<1 year or untreated). (C) Caucasian cohort controlled for population stratification and genotyped for LTBP4
rs10880 (n5115), grouped 2 ways by rs10880 genotype (black line5TT; gray line5CC/CT). (D) Caucasian cohort controlled
for population stratification and genotyped for LTBP4 rs10880 (n5115), grouped 4 ways by rs10880 genotype (black
line5TT; gray line5CC/CTy) and GC treatment (continuous lines5 at least 1 year while ambulatory; dashed lines5<1 year or
untreated).
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MDS Analysis Shows Admixture and Population
Stratification
MDS analysis was based on the calculation of identity-
by-state pairwise distances, performed on 175 partici-
pants with available genome-wide markers. Compared to
108 patients excluded from this analysis because of
unavailability of genome-wide markers (DNA quantity
and quality not sufficient for SNP chip analysis), there
were no significant differences in GC treatment rate
(75.0% vs 76.5%) or median age at LoA (13.0 vs 12.0
years, log-rank p5 0.12, Supplementary Fig).
MDS analysis identified a first principal component
with lower values for participants of European ancestry.
This component is plotted on the x-axis in Figure 4. The
y-axis represents the second principal component. On
the left side of the plot (low values of first principal com-
ponent), 118 participants self-identifying mostly as non-
Hispanic Caucasian (n5 115), and rarely as Hispanic-
Caucasians (n5 2) or Other (n5 1), are clustered closely
together, indicating a subcohort of relatively homogene-
ous European ancestry. Of the remaining 57 patients
with higher values of the first component, 12 self-
identified as non-Hispanic Caucasian, appearing as
“outliers” on the right side of the plot, and indicating
admixture and population stratification within self-
identified Caucasian participants.
Association Analyses in the Caucasian Cohort
Controlled for Population Stratification Lead to
Validation of Both SPP1 and LTBP4 Association
with Age of LoA
As MDS analysis showed population stratification within
self-identified racial–ethnic groups, to adjust for
population-related confounding factors in genetic associa-
tion, we restricted subsequent analyses to 118 patients
showing no evident population stratification (see Fig 1).
Of these, 116 were successfully genotyped for SPP1
rs28357094. Median ages at LoA were 12.0 and 13.9
years, n5 35 and 81 for TG/GG and TT, respectively
(log rank p5 0.047, see Fig 2C). In the Cox regression
model with GC treatment as time-varying covariate, the
HR for TG/GG genotype was 1.546 0.17 (p5 0.09),
and the HR for GC treatment was 0.266 0.07
(p< 0.001).
Of the participants described above, 93 were treated
with GC for at least 1 year while ambulatory. For these
patients, KM median ages at LoA were 12.0 and 13.9
years for TG/GG and TT genotypes, n5 26 and 67
(log-rank p5 0.07, see Fig 2D). When applying the Cox
regression model with GC treatment as time-varying
covariate, HR for TG/GG genotype was 1.856 0.57
(p5 0.047). The HR for GC treatment was 0.726 0.39
(p5 n.s.). In 23 GC-untreated patients, KM median ages
at LoA were 9.0 and 10.0 years for TG/GG and TT
(n5 9 and 14, respectively, p5 n.s., see Fig 2D).
Of 118 participants in the Caucasian cohort con-
trolled for population stratification, 115 were genotyped
for LTBP4 rs10880. KM curves plotted for this group
showed delayed median LoA (15.0 years) in 12 partici-
pants carrying the TT genotype, in contrast to 103 carry-
ing the CC/CT genotype (12.6 years, log-rank
p5 0.024, see Fig 3C). Of these 12 participants, 9 were
homozygotes for the full IAAM haplotype, whereas 3
were heterozygotes for IAAM and other rare LTBP4 hap-
lotypes (VAAM and VTTM). In the Cox regression
model with GC treatment as time-varying covariate, HR
for TT genotype was 0.496 0.19 (p5 0.07). The HR
for GC treatment was 0.266 0.07 (p< 0.001).
Of the participants described in the previous para-
graph, 91 were GC treated for at least 1 year before
LoA. Within this group, KM median age at LoA was
16.0 years for TT genotype and 13.8 for CC/CT, n5 11
and 80 (log-rank p-value5 0.046, see Fig 3D). The Cox
FIGURE 4: Cartesian plot of multidimensional scaling analy-
sis of genome-wide marker population stratification. Values
of the 2 highest ranking components are shown (1st on the
x-axis and 2nd on the y-axis). Shape and color of the
markers indicate self-identified ethnicity. Participants self-
identifying as non-Hispanic Caucasian, indicated by x-
shaped markers, form a cluster with low values of the first
component (< 20.0025, vertical cutoff line). Forty-five par-
ticipants with other self-identified races and ethnicities are
mostly positioned right of the cutoff line: African American
(filled circles), Asian (filled squares), Hispanic Caucasian
(empty triangles), Hispanic (filled triangles), and Other
(empty circles). Twelve participants self-identifying as non-
Hispanic Caucasians appear as outliers, whereas 3 partici-
pants self-identifying as Hispanic Caucasian or Other cluster
together with non-Hispanic Caucasians and are included in
subsequent analyses.
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regression model with GC treatment as time-varying
covariate showed an HR for TT genotype of 0.476 0.20
(p5 0.08). The HR for GC treatment was 0.756 0.40
(p5 n.s.). The presence of just 1 GC-untreated partici-
pant with rs10880 TT genotype precludes statistical anal-
ysis of GC-untreated participants for LTBP4 in this
subgroup.
Taken together, these findings support the protec-
tive effect of the rs10880 TT genotype described by Fla-
nigan et al.9 This was confirmed by reanalyzing CINRG-
DNHS data with the 6-month GC treatment threshold
used in the original report. All KM and Cox regression
parameters for this reanalysis are shown in Supplemen-
tary Table 2.
Discussion
We aimed to study the effect of 2 genetic modifiers on
DMD phenotype, using age at LoA as a disease severity
indicator, in the CINRG-DNHS cohort. This cohort
includes 340 participants followed longitudinally for an
average of 4 years, and the study design and baseline
data have been recently reported.18,19 We grouped partic-
ipants by genotype at 2 loci associated with age at LoA
in DMD (SPP1 rs283570944 and LTBP4 haplotype9).
We had previously reported a cross-sectional analysis of
grip strength as a function of SPP1 genotype in a subset
of this cohort (n5 156), not stratified for ethnicity.
Here, we report time to event analyses for age at LoA in
the complete CINRG-DNHS cohort (except 57 partici-
pants with unavailable DNA samples) for both the SPP1
and LTBP4 loci, controlling for population stratification
and GC treatment as possible confounders.
It is well established that different ethnic groups
show different MAFs for any specific genetic polymor-
phism, as well as different LD between genetic markers
and functional variants. This can lead to hidden popula-
tion stratification even within self-identified racial/ethnic
groups, and thus to false-positive or false-negative find-
ings in genetic association. The CINRG-DNHS cohort
recruited participants from 20 clinical centers in 4 differ-
ent continents, and is ethnically heterogeneous, although
with a majority of Caucasian participants. Both previous
reports14,15,17 and observed tendencies of the phenotype
to differ between ethnic groups in our data further stress
the importance of accounting for population stratifica-
tion issues. Conversely, because of inherent study design
characteristics of the CINRG-DNHS, which did not
purposely recruit representative racial/ethnic subgroups,
conclusive statements cannot be made about racial/ethnic
disparities in DMD, based on our data.
The second potential confounding factor, GC treat-
ment, is probably the single environmental factor most
heavily affecting age at LoA in DMD.22–25 We accounted
for it by implementation in time to event models, as a
grouping criterion for KM analyses and a time-varying
covariate for Cox regression. Because of CINRG-DNHS
population characteristics, that is, a numerical predomi-
nance of GC-treated participants, our findings can be
generalized more confidently to GC-treated DMD popu-
lations. Nevertheless, this is more relevant for patient
care and clinical trials, as GC treatment is considered a
standard of care,2 and often an inclusion criterion in
clinical trials of new treatments.
We first studied SNP effects in the entire cohort
with available DNA samples, without grouping for GC
treatment or ethnicity. The SPP1 rs28357094 G allele,
in a dominant model, was associated with 1.2-year earlier
median LoA. This reproduces the methodology of the
original report4 and represents an independent validation
of association with LoA. The recessive LTBP4 rs10880 T
allele, in close LD with the IAAM haplotype, showed a
direction of association as previously reported,9 but not a
statistically significant difference.
We then grouped participants genotyped for SPP1
and LTBP4 by GC treatment. In our baseline analysis of
156 DNHS participants, the association of SPP1 geno-
type with grip strength showed the largest effect in GC-
treated participants4; and an 80-patient Italian cohort, in
which the association was established with longitudinal
changes of ambulation-related functional measures,26 was
almost entirely GC treated. In line with these previous
findings, which suggest a stronger modifier role of SPP1
in GC-treated patients, an effect of SPP1 genotype on
LoA in the CINRG-DNHS cohort was observed in the
GC-treated subgroup (see Fig 2B). This finding supports
a role of SPP1 rs28357094 as a modulator of GC
response in DMD, rather than of disease progression
itself. This is in concordance with several preclinical
studies of SPP1 promoter function; the minor G allele at
rs28357094 decreases transcriptional activity of the gene
at baseline,6 but shows a 3-fold increase in gene expres-
sion in response to steroids, whereas the common allele
leaves expression unchanged by steroids.7 Consistent with
a steroid-induced alteration of SPP1 expression, differen-
ces in SPP1 mRNA levels between genotypes were not
found in vivo in DMD diagnostic muscle biopsies
obtained prior to GC treatment.27 Evidence of a sexually
dimorphic effect of rs28357094 genotype on muscle size
and remodeling in Caucasian women,28 and of an
increased transcriptional response of the SPP1 promoter
to estrogen stimuli,7 are consistent with a pharmacody-
namic role of this genetic biomarker. GCs are well-
known transcriptional regulators of inflammation-related
genes,29 both directly, through positive or negative GC-
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responsive elements (GREs), and indirectly, through sup-
pression of other transcription factors (eg, NF-jB); and
these mechanisms are relevant to GC efficacy and possi-
bly side effects in DMD.30,31 The SPP1 promoter is pre-
dicted to contain both GREs and NF-jB–responsive
sites, and further studies are needed to dissect these
mechanisms both in vitro and in vivo. To our knowl-
edge, this is the first demonstration of a pharmacody-
namic biomarker for response to GCs, and this may be
relevant to other conditions where GCs are standard of
care. Our data, combined with the recent publication of
Barfield et al,7 suggest that the 20 to 30% of DMD
patients with the rare SPP1 allele are poor responders to
GCs, possibly with an altered balance between beneficial
and side effects. Future studies are needed to confirm
this association, before routine genotyping of SPP1 is
considered as part of standard of care in DMD.
Flanigan et al9 described a larger effect of the pro-
tective LTBP4 variant in GC-treated patients than in
untreated patients. In the CINRG-DNHS cohort, when
stratifying by GC treatment and LTBP4 genotype, we
did not observe differences in genotype effect between
the treated and untreated populations. Reanalyzing data
with the same GC treatment threshold (at least 6 months
before LoA) as in the original report did not modify
these findings (see Supplementary Table 2).
To adjust for potential population stratification
bias, we performed MDS analysis on a subgroup of 175
participants. This showed that the correspondence
between self-identified ethnicity and unbiased grouping
determined by genotype identity was partial, with several
outlier self-identifying Caucasian participants (admix-
ture). Subsequently, we selected MDS rather than self-
identification as a method to adjust for population strati-
fication. A limitation of this study is the unavailability of
genome-wide markers in the whole cohort, which would
have allowed the selection of a larger homogeneous sub-
cohort. However, the reason for exclusion of 108 patients
was technical (DNA sample quality and quantity) and
not linked to any clinically relevant variables. Further-
more, we verified that excluded patients did not signifi-
cantly differ in terms of GC treatment and age at LoA
(see Supplementary Fig). Thus, we expect the cohort ana-
lyzed by MDS to be representative of the whole
CINRG-DNHS.
In the smaller but more homogeneous MDS-
selected Caucasian subcohort, LTBP4 rs10880 was con-
firmed as a strong modifier of ambulatory function in
DMD, with a median age at LoA in carriers of the pro-
tective genotype of 15.0 years overall, and 16.0 years in
those with GC treatment (see Fig 3C–D), which posi-
tions >50% of these patients within the “intermediate
dystrophinopathy” clinical spectrum. The stronger associ-
ation of rs10880 in Caucasians did not seem to be in
direct relation with a stronger LD with the full IAAM
haplotype (see Supplementary Table 1), although num-
bers are too small to reach a conclusion (ie, very few
patients with rare haplotypes). It could also be hypothe-
sized that in Caucasians the T allele for rs10880 might
be in stronger LD with another unrecognized, functional
variant, than in patients with different ancestries. Con-
versely, Flanigan et al did not find additional nonsynony-
mous coding variation by resequencing 40 chromosomes
and querying the 1000 Genomes database, and con-
ducted in vitro experiments showing an effect of the cod-
ing haplotype on TGFb signaling, in conditions of equal
LTBP4 protein expression.9 As for SPP1 rs28357094, the
effect on age at LoA in the Caucasian subcohort appears
smaller in magnitude than that of the LTBP4 haplotype.
This is similar to what was described in the single center
cohort from Padua,4 which was recruited from a homo-
geneous Caucasian population (great majority from
northeastern Italy) with a predominance of GC-treated
participants.
Recently, another genetic modifier study in DMD
was published by a collaborative European group,32 fur-
ther confirming the effect of the LTBP4 IAAM haplotype
in delaying LoA. Conversely, the SPP1 association was not
replicated in 336 patients, of whom 102 had been treated
with GCs for at least 1 year while ambulatory. If SPP1 is
a modifier of GC response, as our association data and in
vitro findings suggest, this low GC treatment rate might
have limited the power of this part of the study.
Lastly, although the genetic modifiers described here
seem to explain some of the variance of the LoA pheno-
type in DMD, both from our data and from case reports
of outlier DMD phenotypes33 it appears that several other,
yet uncharacterized genetic factors must be at play.
In conclusion, our findings show that SPP1
rs28357094 acts as a modifier of the long-term effect of GC
treatment in the CINRG-DNHS. Furthermore, we confirm
that LTBP4 rs10880 modifies age at LoA in DMD. Our
data also stress the importance of adjusting for GC treat-
ment and population substructure in genetic association
studies in DMD. These findings are relevant for future anal-
yses of observational and interventional studies involving
international, multicentric, ethnically diverse cohorts.
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